Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Institutional and Insider Ownership
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Rigel Pharmaceuticals and Lucid Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rigel Pharmaceuticals | 106.59% | 14.89% | 11.99% |
| Lucid Diagnostics | -892.75% | N/A | -142.71% |
Analyst Recommendations
This is a summary of recent ratings for Rigel Pharmaceuticals and Lucid Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rigel Pharmaceuticals | 0 | 3 | 3 | 0 | 2.50 |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
Rigel Pharmaceuticals currently has a consensus target price of $66.75, suggesting a potential upside of 49.09%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 849.55%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Rigel Pharmaceuticals.
Earnings & Valuation
This table compares Rigel Pharmaceuticals and Lucid Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rigel Pharmaceuticals | $288.21 million | 2.93 | $367.02 million | $15.51 | 2.89 |
| Lucid Diagnostics | $5.44 million | 16.49 | -$58.01 million | ($0.40) | -1.10 |
Rigel Pharmaceuticals has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Rigel Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats Lucid Diagnostics on 9 of the 14 factors compared between the two stocks.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.
About Lucid Diagnostics
Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
